ArticleScientific reports2026
Increased risk of cardiovascular diseases among patients with carpal tunnel syndrome in a multicenter global retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Carpal tunnel syndrome (CTS) is linked to cardiovascular outcomes such as cardiac amyloidosis, but prior studies with limited scope leave uncertainty about its role as an marker of other major cardiovascular diseases such as stroke and myocardial infarction. The aim of this study is to evaluate cardiovascular risks in CTS using large-scale global electronic health records. We conducted a retrospective cohort study using TriNetX Global Collaborative Network from a cohort of 619,538 patients with CTS and 8,630,919 CTS-free controls. To minimize confounding, a 1:1 propensity-score matching strategy was employed, creating two well-balanced cohorts of 615,201 patients each. We assessed the risk for a comprehensive range of acute and chronic cardiovascular events and compared the risk in CTS patients with active comparator cohorts of patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Following propensity matching, patients with CTS had a significantly increased risk for ischemic stroke (HR = 1.39, 95% CI, 1.35–1.44) and haemorrhagic stroke (HR = 1.34, 95% CI, 1.26–1.43) compared to controls. This excess risk extended to other cardiovascular outcomes, including acute myocardial infarction (HR = 1.58, 95% CI, 1.53–1.64), heart failure (HR = 1.51, 95% CI, 1.47–1.55), and cerebrovascular disorders (HR 1.62, 95% CI, 1.57–1.67). The strongest association was observed for cardiac amyloidosis (HR = 2.41, 95% CI, 2.07–2.80). These elevated risks were consistent across subgroups stratified by age, sex, and race. Notably, the risk of stroke in the CTS cohort was higher than in both the RA and AS cohorts. The findings remained robust in multiple sensitivity analyses. CTS is associated with increased risk of diverse cardiovascular diseases, with risks exceeding those of established inflammatory conditions such as RA and AS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.